#楽天メディカル と #日本頭頸部癌学会が、5月15日の #ヴィッセル神戸 ホーム公式戦で共催した「楽天メディカル 頭頸部がん克服デー」のダイジェスト動画を公開! スポーツ×疾患啓発でサポーターに #頭頸部がん 予防や早期発見の呼びかけをしました! ◆ダイジェスト動画は👇 https://bit.ly/3VFI8xj
Rakuten Medical’s Post
More Relevant Posts
-
Attending #BIOAsiaTaiwan2024? Rakuten Medical's Chief of Staff Louise Chang will present at BIO Asia–Taiwan in Taipei. Stop by Room 402A, 4F, TaiNEX at 12:00 PM, July 25 to learn more about our investigational #Alluminox™ platform.
To view or add a comment, sign in
-
Join us on Thursday, June 20 at 1:00 pm ET / 10:00 am PT for Rakuten Medical’s virtual R&D Day, featuring Dr. Ann Gillenwater (MD Anderson Cancer Center), discussing the interim evaluation update of the Phase 1b/2 clinical trial of #photoimmunotherapy based on #Alluminox™ platform using ASP-1929 in combination with anti-PD-1 therapy in first line recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma. Register here: https://lnkd.in/gWmJPTzb Learn more at: https://lnkd.in/gVfYgw4f
To view or add a comment, sign in
-
Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox
To view or add a comment, sign in
-
Rakuten Medical' s poster presentation at #ASCO24 will be taking place tomorrow.
Rakuten Medical is excited to announce a poster presentation on the updated safety and efficacy findings from an interim evaluation of ASP-1929-181 study (NCT04305795) at #ASCO24. Our booth will be set up in the exhibit hall during the conference. [Rakuten Medical Booth] - Location: Exhibit Hall A, Booth #12118 - Exhibit Date: Saturday – Monday, June 1 - 3, 2024 Read the release: https://lnkd.in/gpdqPkgC #photoimmunotherapy
To view or add a comment, sign in
-
Attending #BIO2024? Rakuten Medical COO Abhijit Bhatia, MS, MBA will present at BIO International Convention in San Diego. Stop by Company Presentation Theater 1 at 12:15 PM, June 5 to learn more about our investigational #Alluminox platform. We are happy to connect and explore potential partnerships. Please don't hesitate to reach out to us at partnerships@rakuten-med.com.
To view or add a comment, sign in
-
Join us for a virtual R&D Day at which Rakuten Medical will share interim evaluation update of the Phase 1b/2 clinical trial of #photoimmunotherapy based on #Alluminox™ platform using ASP-1929 in combination with anti-PD-1 therapy in first line recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma. Register here: https://lnkd.in/gWmJPTzb Learn more at: https://lnkd.in/gVfYgw4f
To view or add a comment, sign in
-
Thank you Nasdaq for celebrating Rakuten Medical’s announcement of recent interim data from Phase 1b/2 study of ASP-1929 #photoimmunotherapy in combination with anti-PD-1 for the first-line recurrent and/or metastatic head and neck. We look forward to sharing this exiting data with global oncology experts at #ASCO24. Learn more at: https://lnkd.in/gBjPvGzi #Alluminox™
To view or add a comment, sign in
-
Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. Rakuten Medical is excited to announce the updated safety and efficacy findings from an interim evaluation of an open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for first-line recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented in a poster at #ASCO24. Rakuten Medical recently completed a Type B End-of-Phase 2 (EOP2) meeting with the US FDA for the combination of ASP-1929 photoimmunotherapy and anti-PD-1 in the first-line recurrent HNSCC setting and discussed the key details for a multi-regional registrational study. Rakuten Medical plans to initiate this global phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox
To view or add a comment, sign in
8,943 followers